Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCVMUL)

Drug Name

MGD013 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Phase 1/2	[1]
Hematologic tumour	2B33.Y	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	5.635	4.661	4.706	5.15

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hepatocellular carcinoma

ICD Disease Classification

2C12.02

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	7.26E-01	-0.01	-0.03

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04212221) MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients. U.S. National Institutes of Health.
2	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.